Pharvaris (PHVS) Free Cash Flow (2020 - 2026)
Pharvaris' (PHVS) quarterly Free Cash Flow came in at -$57.0 million in Q1 2026, down 41.52% YoY from -$97.5 million in Q1 2025, and down 29.1% on a QoQ basis from -$44.2 million in Q4 2025.
Pharvaris (PHVS) Free Cash Flow (2020 - 2026) Analysis & Trends
Pharvaris (PHVS) has 7 years of Free Cash Flow data on file, last reported at -$57.0 million in Q1 2026.
- Quarterly Free Cash Flow fell 41.52% year-over-year to -$57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$171.0 million (down 19.21% YoY) and the FY2025 annual result came in at -$154.7 million, down 19.5% from the prior year.
- Free Cash Flow fell to -$57.0 million in Q1 2026, from -$44.2 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $49676.0 billion in Q3 2023 to a low of -$49691.2 billion in Q2 2023.
- A 5-year average of -$926.4 million and a median of -$29.8 million in 2024 frame the typical range for Free Cash Flow.
- The widest YoY moves for Free Cash Flow: up 325629580.06% in 2023, down 340811256.1% in 2023.
- Tracing PHVS's Free Cash Flow over 5 years: stood at -$20.8 million in 2022, then dropped by 23.0% to -$25.6 million in 2023, then sank by 45.31% to -$37.2 million in 2024, then retreated by 18.82% to -$44.2 million in 2025, then decreased by 29.1% to -$57.0 million in 2026.
- The last three Free Cash Flow figures came in at -$57.0 million (Q1 2026), -$44.2 million (Q4 2025), and -$35.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Pharvaris | 2.29 Bn | 1.92 Bn | - | -44.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -44.09 Mn |
| Jun 30, 2026 | -44.09 Mn |
| Mar 31, 2026 | -57.03 Mn |
| Mar 31, 2026 | -57.03 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Dec 31, 2025 | -44.18 Mn |
| Sep 30, 2025 | -35.83 Mn |
| Sep 30, 2025 | -35.83 Mn |
| Jun 30, 2025 | -33.96 Mn |
| Jun 30, 2025 | -33.96 Mn |
| Mar 31, 2025 | -40.30 Mn |
| Mar 31, 2025 | -40.30 Mn |
| Dec 31, 2024 | -37.18 Mn |
| Dec 31, 2024 | -37.18 Mn |
| Sep 30, 2024 | -36.19 Mn |
| Sep 30, 2024 | -36.19 Mn |
| Jun 30, 2024 | -29.77 Mn |
| Jun 30, 2024 | -29.77 Mn |
| Mar 31, 2024 | -26.29 Mn |
| Mar 31, 2024 | -26.29 Mn |